CLINICAL TRIAL

Back to List of Studies

Status: Closed to Accrual

A Phase 2b/c, Multi-Arm, 2- Stage, Duration Randomized Trial of the Efficacy and Safety of Two to Four Months Treatment with Regimens Containing Bedaquiline OPC-167832, and Sutezolid, Plus Either Pretomanid or Delamanid, in Adults with Pulmonary Tuberculosis

Short Title/Acronym: PAN TB

Description:

This multicenter, two-stage, open-label, randomized trial will aim to assess the efficacy, safety, optimal duration, and pharmacokinetics (PK) of Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS) and Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS) in adult participants with drug sensitive tuberculosis (DS-TB) and rifampicin or multi-drug resistant TB (RR/MDR-TB).

Start Date: January 24, 2023

Eligibility:

  • Participants between 18 and 65 (inclusive) years of age of both sexes will be eligible for the trial if they have recently diagnosed, untreated (≤4 days of treatment), microbiologically confirmed, drug susceptible, pulmonary Tuberculosis.

    • To Participate in the study kindly reach us via:

     socialworkers@tbhivicr.org.ph
     Call or Text for Smart: 09087751951
     Call or Text for Globe: 09958492471